| Literature DB >> 30289689 |
Raphael Sommer1, João Neres1,2, Jérémie Piton1,2, Neeraj Dhar1,2, Astrid van der Sar3, Raju Mukherjee1,2, Thierry Laroche4, Paul J Dyson5, John D McKinney1,2, Wilbert Bitter3, Vadim Makarov6, Stewart T Cole1,2.
Abstract
Benzothiazinones (BTZ) are highly potent bactericidal inhibitors of mycobacteria and the lead compound, BTZ043, and the optimized drug candidate, PBTZ169, have potential for the treatment of tuberculosis. Here, we exploited the tractability of the BTZ scaffold by attaching a range of fluorophores to the 2-substituent of the BTZ ring via short linkers. We show by means of fluorescence imaging that the most advanced derivative, JN108, is capable of efficiently labeling its target, the essential flavoenzyme DprE1, both in cell-free extracts and after purification as well as in growing cells of different actinobacterial species. DprE1 displays a polar localization in Mycobacterium tuberculosis, M. marinum, M. smegmatis, and Nocardia farcinica but not in Corynebacterium glutamicum. Finally, mutation of the cysteine residue in DprE1 in these species, to which BTZ covalently binds, abolishes completely the interaction with JN108, thereby highlighting the specificity of this fluorescent probe.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30289689 DOI: 10.1021/acschembio.8b00790
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100